Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

expressPIK

Financiado

expressTEC - From Launch to First MVP

Over 600k annual new cases of breast cancer worldwide carry poor prognosis mutations in the gene PIK3CA, but since 2020 a targeted therapeutic option – PIQRAY (alpelisib) – became available, exclusively from Novartis. However, due... ver más

30/06/2024

EXPRESSTEC

75K€

Presupuesto del proyecto: 75K€

Líder del proyecto

EXPRESSTEC INVESTIGAO E DESENVOLVIMENTO EM B... No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-06-30

HORIZON-EIE-2022-SCALEUP-02-02: Women TechEU ExpectedOutcome:Project results are expected to contribute to the following expected outcomes:

Innovación

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

EXPRESSTEC

75.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC2019-007229-1 PrediApt: Desarrollo de un Sistema Predictivo de Respuesta a... 128K€ Cerrado

ProstOmics Tissue is the issue a multi omics approach to improve pro... 2M€ Cerrado

RTC-2017-6597-1 AptaLung: Diagnóstico de cáncer de pulmón utilizando tecnolo... 136K€ Cerrado

OvaCTool Personalized medicine in ovarian cancer: Design and developm... 181K€ Cerrado

PTQ2021-011652 Investigación y desarrollo de herramientas para la detección... 70K€ Cerrado

IMPACCT Improved Patient Care by Combinatorial Treatment 145K€ Cerrado

Duración del proyecto: 12 meses Fecha Inicio: 2023-06-01
Fecha Fin: 2024-06-30

Líder del proyecto

EXPRESSTEC INVESTIGAO E DESENVOLVIMENTO EM B... No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 75K€

Descripción del proyecto Over 600k annual new cases of breast cancer worldwide carry poor prognosis mutations in the gene PIK3CA, but since 2020 a targeted therapeutic option – PIQRAY (alpelisib) – became available, exclusively from Novartis. However, due to the still unsatisfactory response rates, the uptake by doctors and the adherence by patients has been limited. Eligibility is established at present by assessing the PIK3CA status in tumour DNA via companion diagnostic (CDx) tests (from Qiagen and Roche). However, we found that the level of expression of the PIK3CA mutations, measured in tumour RNA, associates with prognosis and is more accurate to predict the presence of the final mutated protein (the drug target). Hence, we are developing an innovative CDx – expressPIK - that goes beyond the present ones to test the expression of mutations and correctly identify the patients who will benefit from treatment. Our higher accuracy will increase doctors’ confidence in prescribing expressPIK (profitable for expressTEC and investors), and the better response rate (beneficial to patients) will promote patient uptake and treatment adherence (profitable for Novartis). The total global expressPIK market is over +600 K patients per year. The European Patent pending secures the use of mutation expression levels in clinical diagnosis, for treatment with PIQRAY and other drugs in clinical trials. We are validating the technology and planning to reach the MVP within a year. Women TechEU will support developing our business knowledge and acumen, as well as provide the access to the industry and investors network we are lacking. We hope to make a change in the survivorship of breast cancer patients, whilst setting an example of female entrepreneurship in a region with high unemployment and low biotech investment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores